Systemic @entity10211 Treatment and Pregnancy: A Longitudinal Cohort Study from XXXX .

@entity1 @entity854 @entity10211 @entity233
OBJECTIVE: @entity10211 is known to be the most effective treatment of severe and persistent acne. However, one of the most important adverse effects of this drug is known to be teratogenicity. In this regard, tests are administered before initiating the treatment, to assure that an unknown pregnancy is not present and accordingly, @entity1 are advised to take contraceptive precautions during their systemic @entity10211 treatments. On the contrary, many cases of unwanted pregnancies and relevant abortuses have been reported all over the world. In the Turkish literature, only a few reports have been identified about foetal exposure to @entity10211 . MATERIALS AND METHODS: In this respect, a study was carried out on fifty-seven female @entity1 , aiming to fulfil the gap of information mentioned above. Female @entity1 , with ages ranging between 14 and 35 years, were recruited to the study and they were administered @entity10211 treatments (cumulative dose of 120 mg/kg) for an average period of 6 months. The @entity1 were followed up during and after the treatment for a total period of 18 months. RESULTS: As a result, it has been observed that none of the @entity1 got pregnant during the treatment period and relevantly, no @entity854 were recorded. Moreover, none of the @entity1 got pregnant 12 months after the termination of the treatment. Additionally, the socio-demographic analysis of the @entity1 indicates that most of the @entity1 were single and 81% of the @entity1 were sexually inactive. CONCLUSION: Our findings suggest that the low reportage of teratogenicity due to @entity10211 usage in @entity233 could be due to several reasons, such as the sociocultural profile of the female @entity1 undertaking the @entity10211 treatment, and strict adherence to contraceptive methods, and/or underreporting of teratogenic incidents due to lack of studies held in cooperation with obstetricians.
